Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Up 3.5 %

Shares of Enzo Biochem stock opened at $1.18 on Friday. Enzo Biochem has a twelve month low of $0.99 and a twelve month high of $1.50. The business’s 50 day simple moving average is $1.12 and its 200-day simple moving average is $1.14.

Institutional Trading of Enzo Biochem

Several large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its stake in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares in the last quarter. Wittenberg Investment Management Inc. bought a new position in shares of Enzo Biochem in the fourth quarter valued at approximately $95,000. Finally, Renaissance Technologies LLC raised its position in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the period. 36.90% of the stock is currently owned by institutional investors and hedge funds.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.